Skip to main content

Table 1 Plasmatic levels of IL-1β and TNF-α (pg/mL) in control and two weeks evolution streptozotocin-induced diabetic SD rats, both untreated or receiving i.p. anakinra (AK)

From: The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats

 

Untreated

AK (100 mg/Kg/day for 3 days)

AK (100 mg/Kg/day for 7 days)

AK (160 mg/Kg/day for 3 days)

Control

IL-1β

82.61 ± 5.02

78.59 ± 18.02

77.85 ± 18.55

90.44 ± 18.47

 

TNF-α

11.52 ± 2.71

12.82 ± 3.08

12.39 ± 1.30

10.21 ± 4.34

Diabetic

IL-1β

83.88 ± 10.84

57.11 ± 5.75

45.17 ± 8.48*

42.89 ± 4.92*†

 

TNF-α

11.22 ± 2.05

8.26 ± 2.13

3.48 ± 0.82*†

3.43 ± 1.27*†

  1. Data are expressed as mean ± SE of 4 to 10 determinations. *p < 0.05 vs respective untreated rats; †p < 0.05 vs respective control group.